A Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with lumacaftor/ivacaftor.
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to assess the effect of N91115 on lung function when added to preexisting treatment with ORKAMBI in adult patients with CF who are homozygous for the F508-del-CFTR mutation.
Description
The purpose of this study is to assess the effect of N91115 on lung function when added to preexisting treatment with ORKAMBI in adult patients with CF who are homozygous for the F508-del-CFTR mutation.
Details
| Condition | cystic fibrosis |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX5963 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.